|
|
|
02 Oct 2007 |
FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
|
|
02 Oct 2007 |
Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity
|
|
29 Sep 2007 |
Galvus(R) receives European approval as new treatment for type 2 diabetes with broad range of indications
|
|
27 Sep 2007 |
Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
|
|
27 Sep 2007 |
OctoPlus in-licenses diabetes product candidate
|
|
26 Sep 2007 |
Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
|
|
25 Sep 2007 |
DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug-Compliant Subjects in Phase Ib Clinical Study
|
|
25 Sep 2007 |
Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
|
|
25 Sep 2007 |
ISTO Technologies Receives 510(k) Clearance for a Novel Bone Graft Substitute and Bone Graft Extender
|
|
25 Sep 2007 |
Pacgen Announces Advances in PAC-113 Program
|
|
22 Sep 2007 |
Eucreas(R), a single-tablet combination of Galvus(R) and metformin, recommended for EU approval for type 2 diabetes
|
|
22 Sep 2007 |
One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
|
|
21 Sep 2007 |
Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone Strength in Primate Studies
|
|
20 Sep 2007 |
MIV-701 Preclinical Efficacy Data Presented
|
|
20 Sep 2007 |
Novo Nordisk receives approval in the EU for use of NovoRapid(R) in elderly people
|
|
20 Sep 2007 |
FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
|
|
20 Sep 2007 |
Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C(TM))
|
|
20 Sep 2007 |
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
|
|
19 Sep 2007 |
New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years
|
|
19 Sep 2007 |
FDA Accepts Samaritan's Cushing's
|
|
19 Sep 2007 |
DiaMedica Announces Positive Pre-Clinical Results for DM-83
|
|
19 Sep 2007 |
Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation
|
|
19 Sep 2007 |
Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
|
|
18 Sep 2007 |
First osteoporosis study in patients with hip fracture finds once-yearly Aclasta(R)-Reclast(R) prevents additional fractures and improves survival
|
|
18 Sep 2007 |
A major pharmaceutical company has taken an exclusive option to BA058, a compound licensed by Ipsen to Radius in 2005
|
|
18 Sep 2007 |
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
|
|
18 Sep 2007 |
Phosphagenics to conduct a Phase 1 transdermal oxycodone clinical trial
|
|
18 Sep 2007 |
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
|
|
18 Sep 2007 |
Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303
|
|
18 Sep 2007 |
Metabasis Therapeutics Presents Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes
|
|
17 Sep 2007 |
NeuroSearch announces breakthrough tesofensine results from clinical Phase IIb study in obesity ("TIPO-1")
|
|
15 Sep 2007 |
Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events
|
|
14 Sep 2007 |
Cytopia's FMS inhibitor prevents bone loss in animals
|
|
13 Sep 2007 |
Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
|
|
13 Sep 2007 |
XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
|
|
12 Sep 2007 |
Phosphagenics to commence Phase 2 TPM/Insulin cinical trial
|
|
12 Sep 2007 |
Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
|
|
12 Sep 2007 |
Corcept Therapeutics Receives FDA Notification Opening IND for CORLUX(R) for the Treatment of Cushing's Syndrome
|
|
12 Sep 2007 |
Phenomix Initiates Phase 2b Clinical Trial of PHX1149 for Type 2 Diabetes; Will Present PHX1149 Data at EASD
|
|
07 Sep 2007 |
OSI Pharmaceuticals Announces Positive Results from a Metformin Drug Interaction Study with Its DP-IV Inhibitor, PSN9301
|
|
06 Sep 2007 |
AtheroGenics Announces New ARISE Diabetes Data on AGI-1067 Presented at the European Society of Cardiology Congress 2007
|
|
06 Sep 2007 |
Alba Therapeutics Announces IND for Beta Cell Preservation in Type 1 Diabetes Using AT-1001
|
|
04 Sep 2007 |
Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
|
|
01 Sep 2007 |
AstraZeneca and Abbott Announce Selection of Next-Generation Fenofibrate (ABT-335) and CRESTOR(R)Fixed-Dose Combination
|
|
01 Sep 2007 |
Somatuline(R) Depot receives marketing approval in the United States
|
|
31 Aug 2007 |
KB5359 has been discontinued for further development
|
|
30 Aug 2007 |
Lilly and Takeda to Terminate Joint Development/Co-Marketing Agreement on Ruboxistaurin mesylate, an agent for the treatment of diabetes microvascular complications
|
|
29 Aug 2007 |
Merck Announces FDA Acceptance of NDA for CORDAPTIVE(TM) (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier
|
|
28 Aug 2007 |
Medicis and Hyperion Therapeutics Announce Strategic Collaboration
|
|
28 Aug 2007 |
Indevus Announces Submission of New Drug Application
|
| |
|
Results 401 - 450 of 1042 |
